Eiger BioPharmaceuticals to Host Conference Call to Discuss Phase 3 TOGETHER Study Results of Peginterferon Lambda for COVID-19 on Thursday, March 17, 2022

Rhea-AI Summary

Eiger BioPharmaceuticals (Nasdaq:EIGR) will host a conference call on March 17, 2022, at 5:30 AM Pacific / 8:30 AM Eastern to discuss results from the Phase 3 TOGETHER study of Peginterferon Lambda for COVID-19. The company focuses on innovative therapies for Hepatitis Delta Virus (HDV) and other serious diseases, with multiple programs granted FDA Breakthrough Therapy Designation. Investors can access the live call or replay via the company's website.

Positive

• Successful completion of Phase 3 TOGETHER study.
• Focus on innovative therapies for HDV with FDA Breakthrough Therapy Designation.

Negative

• None.

Live Conference Call and Webcast at 5:30 AM Pacific / 8:30 AM Eastern

PALO ALTO, Calif., March 16, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure Hepatitis Delta Virus (HDV) and other serious diseases, today announced that it will host a conference call on Thursday, March 17, 2022, at 5:30 AM Pacific / 8:30 AM Eastern, to discuss the results from the Phase 3 TOGETHER study of Peginterferon Lambda for COVID-19.

The live and replayed webcast of the call will be available through the company's website at www.eigerbio.com. To participate in the live call by phone, dial (844) 743-2495 (U.S.) or (661) 378-9529 (International) and enter conference ID 8990285. The webcast will be archived and available for replay for at least 90 days after the event.

About Eiger
Eiger is a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure Hepatitis Delta Virus (HDV) and other serious rare diseases. The Eiger HDV platform includes two first-in-class therapies in Phase 3 that target critical host processes involved in viral replication. All five Eiger rare disease programs have been granted FDA Breakthrough Therapy Designation.

For additional information about Eiger and its clinical programs, please visit www.eigerbio.com.

Investors:
Sri Ryali – CFO
sryali@eigerbio.com
Sylvia Wheeler – Wheelhouse Life Science Advisors
swheeler@wheelhouselsa.com 

Media:
Aljanae Reynolds – Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com 
Edelman for Eiger BioPharmaceuticals, Inc.
Eiger@edelman.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/eiger-biopharmaceuticals-to-host-conference-call-to-discuss-phase-3-together-study-results-of-peginterferon-lambda-for-covid-19-on-thursday-march-17-2022-301504360.html

SOURCE Eiger BioPharmaceuticals, Inc.

FAQ

What is the purpose of the TOGETHER study by Eiger BioPharmaceuticals?

The TOGETHER study aimed to evaluate the efficacy of Peginterferon Lambda for treating COVID-19.

When will Eiger BioPharmaceuticals discuss the TOGETHER study results?

Eiger will discuss the results in a conference call on March 17, 2022, at 5:30 AM Pacific / 8:30 AM Eastern.

What is the significance of the FDA Breakthrough Therapy Designation for Eiger BioPharmaceuticals?

The FDA Breakthrough Therapy Designation accelerates the development and review of drugs that may provide substantial improvement over existing therapies.

Where can I access the Eiger BioPharmaceuticals conference call?

The call can be accessed live or replayed through Eiger's website at www.eigerbio.com.

What diseases is Eiger BioPharmaceuticals focused on treating?

Eiger focuses on treatments for Hepatitis Delta Virus (HDV) and other serious rare diseases.